CELZ
Creative Medical Technology Holdings, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.65
P/S
883.19
EV/EBITDA
0.32
DCF Value
$2.95
FCF Yield
-110.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-964.8%
Operating Margin
-102380.2%
Net Margin
-99916.8%
ROE
-85.7%
ROA
-81.0%
ROIC
-81.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $3.0K | $-1.9M | $-0.73 |
| FY 2025 | $6.0K | $-6.0M | $-2.52 |
| Q3 2025 | $0.00 | $-1.2M | $-0.48 |
| Q2 2025 | $0.00 | $-1.2M | $-0.48 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.99
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.